Navigation Links
Luoxis Establishes Study Collaborations with Two Research Centers in Oxidative Stress

GREENWOOD VILLAGE, Colo., Jan. 6, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center (Nahariya, Israel) and the University of Thessaly (Larissa, Greece). These two leading oxidative stress research groups will utilize Luoxis' proprietary RedoxSYS oxidation-reduction potential (ORP) diagnostic system to study oxidative stress markers across hypertension, hemodialysis, sepsis, and physical exertion.



Western Galilee Medical Center, based in Nahariya, Israel, is a leading institution in the study of oxidative stress. Dr. Shifra Sela and Dr. Batya Kristal will serve as the principle investigators studying oxidation-reduction potential in hypertension and hemodialysis.  Both researchers have studied oxidative stress for over 20 years, and their work has been extensively published.

The University of Thessaly, comprising faculties of Medicine, Biochemistry and Biotechnology in Larissa, Greece, is an established institution supported by University Hospital of Larissa and focused on patient care and research, including the study of oxidative stress in critical conditions.  Dr. Maria Karapetsa, Dr. Epaminondas Zakynthinos, Dr. Dimitrios Kouretas, and Dr. Dimitrios Stagos will serve as the principle investigators studying oxidation-reduction potential in sepsis and physical exertion. All researchers have multiple publications to their credit.

"We are pleased to be partnering with Western Galilee Medical Center and the University of Thessaly on these important research projects," said Josh Disbrow, Chief Executive Officer of Luoxis. "Luoxis and these prominent research teams share a strong interest in advancing the study of oxidative stress, and we believe incorporating oxidation-reduction potential measurements into current diagnostic practice will significantly advance assessment of human oxidative stress in prevalent and challenging patient populations."

Both research centers, in collaboration with Dr. David Bar-Or, Ampio and Luoxis Chief Scientific Officer, expect to publish the results of their research in peer-reviewed publications following completion of the studies. 

About the RedoxSYS Diagnostic System
The RedoxSYS diagnostic system is a patented diagnostic device with accompanying disposable sensors that rapidly measures and reports unique oxidative stress parameters by analyzing a single drop of a biologic specimen. Prior to the development of the RedoxSYS diagnostic system, oxidative stress measurement was incomplete, time consuming and impractical in a clinical setting. The RedoxSYS diagnostic system enables robust and rapid assessment of oxidative stress via measurement of oxidation-reduction potential (ORP) in the clinical setting.  ORP is a homeostatic parameter capturing the balance of oxidants and reductants in a biologic system, a complete measure of oxidative stress.  Multiple clinical trials have been completed using the RedoxSYS diagnostic system and have demonstrated the predictive value of ORP across numerous conditions.

About Luoxis
Luoxis is a biotechnology company focused on the development and global commercialization of the RedoxSYS diagnostic system.  The RedoxSYS diagnostic system is comprised of a portable analyzer and disposable sensors that rapidly measure the level of oxidative stress and antioxidant reserves in biologic specimens via assessment of oxidation-reduction potential (ORP). ORP has been shown to be an important measure in both critical and chronic illnesses and is a novel marker of patient morbidity across a wide range of conditions. There are numerous clinical indications for this homeostatic parameter for which there is no currently available test. Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc.

About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.

Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Investor Contact:
Rick Giles
Director of Investor Relations
Ampio Pharmaceuticals, Inc.
Direct: (720) 437-6530

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
2. Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
3. Quantum Materials Establishes Milestone as First Company to Deliver Tetrapod Quantum Dot Samples to LCD Display Manufacturer
4. Texas Childrens Hospital establishes the Jeffrey Modell Diagnostic & Research Center with a donation from the Jeffrey Modell Foundation
5. PA Governor Corbett: Americure Rx Establishes Operations in Lehigh Valley; Creates 51 Jobs
6. Winterhawk Consulting Establishes Partnership with Onapsis Inc to expand their SAP security offerings using Onapsis X1.
7. ICV Partners Establishes Dialysis Treatment Platform With Acquisition Of Atlantis Healthcare Group Puerto Rico, Inc.
8. Life Technologies Establishes International Influenza Network
9. H. D. Smith Establishes Specialty Solutions Organization And Realigns Senior Leadership To Support Growing Geographic Reach, Diversified Businesses
10. PQ Bypass Graduates from the Fogarty Institute for Innovation, Establishes Independent Operations
11. HYCOR Establishes Center Of Operations In Kassel, Germany To Provide Dedicated Support To European Distributors And Customers
Post Your Comments:
(Date:10/8/2015)... October 8, 2015 " Biomedical ... Growth, Trends and Forecast 2014 - 2022 " , ... 2.63 billion in 2013 and is anticipated to expand at ... USD 4.00 billion in 2022. --> " ... Share, Growth, Trends and Forecast 2014 - 2022 " ...
(Date:10/8/2015)... N.C. , Oct. 8, 2015  Clariant, a world ... Packaging manufacturing facility in Belen, New Mexico ... for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site – ... – to meet the ISO 15378:2011 standards, following only the ...
(Date:10/8/2015)... , Oct. 8, 2015  Nektar Therapeutics (Nasdaq: ... pain and oncology portfolio during an Investor and Analyst ... p.m. Eastern Time in New York City ... of the NKTR-214 Phase 1/2 clinical program and biomarker ... cytokine designed to preferentially stimulate the production of CD8-positive ...
Breaking Medicine Technology:
... SHP ) ("ShangPharma" or the "Company"), a ... company, today announced that it will release its unaudited ... ended December 31, 2011 on March 13, 2012. Management ... at 08:00AM New York Time on March 13, 2012 ...
... 28, 2012  Based on its recent analysis of ... Brainsway with the 2012 Global Frost & Sullivan ... Magnetic Stimulation (dTMS) is the only non-invasive technique ... depression and other neuro-psychiatric disorders without causing any ...
Cached Medicine Technology:
(Date:10/9/2015)... CA (PRWEB) , ... October 09, 2015 , ... ... anniversary of their “Agents of Change” program, a community improvement initiative that involves ... newest charity to benefit from the assistance of Confidence Plus Insurance is the ...
(Date:10/9/2015)... ... October 09, 2015 , ... Prescription Hope, the fastest ... of life to save money on the high cost of their prescription medications ... medication, individuals and families can receive their medications delivered direct from over 180 ...
(Date:10/9/2015)... ... October 09, 2015 , ... Santa Rosa Consulting and ... as MD Anderson prepares to go-live on the Epic platform in March of 2016. ... 2016. Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion and the ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... counseling, recently opened its newest office in Maryland – its Bethesda ... a background as a project management technology consultant to many of the largest ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... franchise, was recognized by Cabarrus County Active Living and Parks for its outstanding ... care company’s dedication to consistently going above and beyond the call of ...
Breaking Medicine News(10 mins):
... Latest version of the "All About Me" Children,s Health Journal has just ... and keep track of their childrens, immunizations and developmental progress. It is ... coast to coast have been using it since its inception. A diaper ... ...
... Health Properties, Inc. (NYSE: NHP ) announced the tax treatment for its 2008 dividend ... COMMON STOCK (CUSIP# 638620104), 2008 ... Return Total Unrecaptured, Record ... Capital Section, Date ...
... into effect, granting children 12 years and older a ... right to access condoms. But current policies allow ... out condomspolicies that two researchers, writing in this week,s ... of the country,s youth. , Juliana Han (Harvard Law ...
... lifestyle interventions that not only modify diet and physical ... obese children lose weight and maintain that loss for ... that in adolescents the effect lasts for at least ... to behaviour change programs for adolescents may provide additional ...
... PARK, Calif., Jan. 20 Exponent, Inc. (Nasdaq: ... for the fourth quarter and fiscal year ended January 2, ... February 4, 2009. The Company will host a corresponding ... 1:30 p.m. Pacific Time. Michael Gaulke, Chairman and Chief ...
... researchers say , , TUESDAY, Jan. 20 (HealthDay News) -- ... a saliva test for monitoring type 2 diabetes, which ... first time, researchers from Oregon and India have identified ... with diabetes than in non-diabetics. Using these proteins, they ...
Cached Medicine News:
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
Medicine Products: